Sign in
Taking peoplePhase 4

Fufang Congrong Yizhi Capsules (FCYC) of Cognitive Impairment After Intracerebral Hemorrhage

Key facts

Who runs it
Qinhuangdao Hospital of Traditional Chinese Medicine
Where
China6 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 4
People taking part
200 people, planned
Started
4 Nov 2024
Planned end
30 Jun 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • FCYC+Conventional treatment
  • conventional treatment
Record updated
6 November 2024

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (16)Hide the full registry criteria

Who can take part

  • Meet the diagnostic criteria of intracerebral hemorrhage (ICH) and use a neurosurgical robot to treat ICH
  • Meet diagnostic criteria for post-stroke cognitive impairment (PSCI)
  • Meet traditional Chinese medicine (TCM) diagnosis of deficiency of the liver and kidney, phlegm and stagnant blood obstructing the meridians pattern
  • Aged 18 and above
  • Not limit gender
  • 2 weeks after the onset of ICH
  • The participants are conscious, possess sufficient visual and auditory recognition, and are capable of undergoing neuropsychological evaluation
  • Submit informed consent

Who cannot take part

  • Patients with alcohol or drug dependency diagnosed within 6 months
  • Other types of dementia besides vascular dementia (VD), such as Alzheimer's disease(AD), dementia with Lewy bodies (DLB), and frontotemporal dementia
  • Patients with other systemic diseases that can affect cognitive function, such as Parkinson's disease (PD), normal pressure hydrocephalus (iNPH), brain tumor, encephalitis, thyroid dysfunction, severe anemia, syphilis, and acquired immune deficiency syndrome(AIDS)
  • Patients with communication difficulties, patients with mental illness
  • Patients with severe liver, kidney, or heart failure or other serious primary diseases
  • Patients are unable to participate in the examination who have severe visual or auditory impairments, apraxia, aphasia, or apparent neurological abnormalities
  • Patients with depression, Hamilton Depression Scale ( HAMD ) ≥ 17 points
  • Preconceptional, lactating, and pregnant women

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Cognitive impairment or intracerebral hemorrhage

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a randomized, controlled clinical study conducted across multiple centers. The neurosurgical robot can be used to treat patients with acute intracerebral hemorrhage (ICH). Establish a cohort comprising 200 participants with cognitive impairment after robot-assisted neurosurgery treatment for ICH. Two hundred participants are randomly assigned to either an experimental group (n=100) or a control group (n=100). The experimental group receive conventional treatment and oral administration of Fufang Congrong Yizhi Capsules (FCYC) for 12 weeks, while the control group receive only conventional treatment. The object of the current study is 1) to observe the security and effectiveness of FCYC and 2) to decipher the contributing factors to cognitive impairment after robot-assisted neurosurgery treatment for intracerebral hemorrhage.

The 2 groups in the trial

  • Conventional treatment groupExisting treatment, for comparison

    Conventional treatment: blood pressure control and care as according to the current guidelines

    Treatment: conventional treatment

  • FCYC groupTreatment being tested

    Conventional treatment combined with oral administration of FCYC (four capsules, three times a day, orally) for a 12-week course of treatment

    Treatment: FCYC+Conventional treatment

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Safety and Efficacy of Fufang Congrong Yizhi Capsules (FCYC) to Cognitive Impairment After Robot-assisted Neurosurgical Management for Intracerebral Hemorrhage(CONPAIR)
Criteria questions
Built from NCT06673602, who can take part
Record updated
6 November 2024